Quality By Design (Qbd)-Driven Development of Herbal Transdermal Drug Delivery Systems: Advances, Regulatory Perspectives, And Future Directions

The increasing global reliance on herbal medicines has stimulated substantial interest in the development of advanced drug delivery systems capable of overcoming the inherent limitations associated with phytopharmaceuticals. Herbal drugs, despite their long-standing therapeutic use and favorable safety profiles, often suffer from poor aqueous solubility, low bioavailability, rapid metabolism, and instability of active phytoconstituents, which ultimately compromise their clinical efficacy [1,2]. Additionally, the complex and multicomponent nature of herbal extracts leads to variability in pharmacokinetic and pharmacodynamic responses, posing significant challenges in achieving consistent therapeutic outcomes [3]. In recent years, transdermal drug delivery systems (TDDS) have emerged as a promising alternative to conventional oral and parenteral routes of drug administration. TDDS offer several advantages, including bypassing hepatic first-pass metabolism, maintaining sustained and controlled drug release, reducing dosing frequency, and enhancing patient compliance [4,5]. Furthermore, transdermal systems provide a non-invasive route that minimizes gastrointestinal irritation and improves drug stability compared to oral formulations. However, the effectiveness of TDDS is largely limited by the barrier function of the stratum corneum, the outermost layer of the skin, which restricts the permeation of hydrophilic molecules and compounds with high molecular weight (>500 Da) [6]. This barrier necessitates the use of permeation enhancement strategies such as chemical enhancers, vesicular systems, and physical techniques including microneedles and iontophoresis. To systematically address formulation and process-related challenges, the pharmaceutical industry has increasingly embraced the Quality by Design (QbD) approach. QbD is a science- and risk-based framework that emphasizes predefined objectives, comprehensive process understanding, and control strategies to ensure consistent product quality. The concept is strongly supported by regulatory authorities through guidelines such as ICH Q8 (R2) for pharmaceutical development, ICH Q9 for quality risk management, ICH Q10 for pharmaceutical quality systems, and the recently introduced ICH Q14 for analytical procedure development, which collectively advocate a lifecycle approach to product development and quality assurance [7–9]. By identifying and controlling critical variables such as Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs), QbD facilitates robust formulation development and reduces variability in final products. The application of QbD is particularly crucial in the formulation of herbal transdermal patches due to the inherent variability and complexity of plant-derived materials. Factors such as geographical origin, harvesting conditions, extraction methods, and storage significantly influence the composition of phytoconstituents, leading to batch-to-batch inconsistency and challenges in standardization [10]. Moreover, interactions between herbal components and excipients may further affect drug release, stability, and permeation characteristics. Therefore, a systematic QbD approach incorporating risk assessment tools and Design of Experiments (DoE) is essential for optimizing formulation variables and ensuring reproducibility. Recent advancements (2021–2025) have demonstrated that integrating QbD with emerging technologies such as nanotechnology, microneedle-assisted delivery, iontophoresis, and artificial intelligence (AI)-driven modeling can significantly enhance the performance of herbal transdermal systems [11–13]. Nanocarriers such as liposomes, ethosomes, and nanoemulsions improve the solubility and skin permeation of phytoconstituents, while microneedle systems enable minimally invasive delivery across the stratum corneum. Additionally, AI-based predictive modeling has shown great potential in optimizing formulation parameters, reducing experimental workload, and accelerating product development. In this context, the present review aims to provide a comprehensive and critical overview of QbD-based formulation strategies for herbal transdermal patches. The review highlights key principles of QbD, recent technological advancements, regulatory perspectives, and future opportunities in the development of robust, safe, and efficacious phytopharmaceutical transdermal systems.

2. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS)

Transdermal drug delivery systems (TDDS) represent a non-invasive and advanced approach for the systemic administration of drugs through the skin. These systems are designed to deliver therapeutically effective concentrations of drugs across the skin barrier into systemic circulation at a controlled rate. Over the past few decades, TDDS have gained considerable attention due to their ability to improve pharmacokinetic profiles, enhance patient compliance, and minimize systemic side effects associated with conventional dosage forms [11,12].

2.1 Structure of Transdermal Patches

A typical transdermal patch is a multi-layered system composed of different functional components, each playing a crucial role in drug delivery performance:

1. Backing Layer

The backing layer is the outermost layer of the patch and serves as a protective barrier against environmental factors such as moisture, oxygen, and mechanical damage. It is generally composed of impermeable materials such as polyethylene, polyester, or aluminized films, ensuring unidirectional drug flow toward the skin [13].

2. Drug Reservoir/Matrix Layer

This layer contains the active pharmaceutical ingredient (API) either dissolved or dispersed in a polymer matrix. In reservoir systems, the drug is contained in a liquid or gel reservoir separated by a rate-controlling membrane, whereas in matrix systems, the drug is uniformly distributed within a polymeric network. The physicochemical properties of the drug and polymer significantly influence the release kinetics [14].

3. Adhesive Layer

The adhesive layer ensures intimate contact between the patch and the skin surface. Pressure-sensitive adhesives (PSAs), such as acrylics, silicones, or polyisobutylenes, are commonly used due to their biocompatibility and ability to maintain adhesion over extended periods. In some systems, the drug may also be incorporated directly into the adhesive layer (drug-in-adhesive systems) [15].

4. Release Liner

The release liner is a protective layer that covers the adhesive surface during storage and is removed prior to application. It is typically made of materials such as silicone-coated paper or polymer films that prevent drug loss and contamination [16].

2.2 Types of Transdermal Patches

Transdermal patches can be classified based on their design and drug release mechanisms:

1. Matrix Systems

In matrix patches, the drug is uniformly dispersed within a polymer matrix, and drug release occurs through diffusion. These systems are widely used due to their simplicity, flexibility, and cost-effectiveness [17].

2. Reservoir Systems

Reservoir patches consist of a drug reservoir enclosed between the backing layer and a rate-controlling membrane. These systems provide precise control over drug release but carry a risk of dose dumping if the membrane is compromised [18].

3. Drug-in-Adhesive Systems

In this design, the drug is directly incorporated into the adhesive layer, simplifying the patch structure and improving patient compliance. These systems are commonly used in commercial products [19].

4. Microneedle Patches

Microneedle-based patches are an advanced form of TDDS that utilize micron-scale needles to penetrate the stratum corneum, thereby enhancing drug permeation without causing pain or bleeding. These systems are particularly useful for delivering macromolecules and poorly permeable drugs [10].

5. Vapor Patches

Vapor patches release volatile active ingredients (e.g., essential oils) that are absorbed through the skin or inhaled. These are commonly used for aromatherapy and symptomatic relief [21].

2.3 Advantages of TDDS

• Transdermal drug delivery systems offer several advantages over conventional dosage forms:
• Controlled Drug Release: TDDS provide sustained and controlled drug delivery, maintaining steady plasma drug concentrations and reducing fluctuations [12].
• Improved Bioavailability: By bypassing hepatic first-pass metabolism, TDDS enhance the bioavailability of drugs that undergo extensive metabolism when administered orally [1].
• Reduced Dosing Frequency: Prolonged drug release reduces the need for frequent dosing, thereby improving patient adherence [13].
• Enhanced Patient Compliance: Non-invasive and convenient application improves patient acceptability, particularly in chronic therapies [2].
• Minimized Side Effects: Controlled delivery reduces peak plasma concentrations, thereby lowering the risk of adverse effects [14].

2.4 Limitations of TDDS

• Despite their advantages, TDDS have several limitations that restrict their universal application:
• Skin Barrier Resistance: The stratum corneum acts as a major barrier, limiting drug permeation, especially for hydrophilic and high molecular weight compounds (>500 Da) [20].
• Limited Drug Permeability: Only drugs with suitable physicochemical properties (low molecular weight, moderate lipophilicity) can be effectively delivered through the skin [16].
• Risk of Skin Irritation: Prolonged application of patches may cause irritation, sensitization, or allergic reactions due to adhesives or excipients [17].
• Variability in Skin Permeation: Factors such as age, hydration, skin condition, and anatomical site can influence drug absorption [18].

3. MECHANISM OF SKIN PERMEATION

The skin acts as a highly efficient protective barrier, regulating the entry of exogenous substances into the body. It is composed of three primary layers: the epidermis, dermis, and hypodermis. Among these, the stratum corneum (SC)—the outermost layer of the epidermis—is the principal barrier to drug permeation. It consists of dead, keratinized corneocytes embedded in a lipid matrix composed of ceramides, cholesterol, and free fatty acids, often described as a “brick-and-mortar” structure [21,22]. Drug permeation through the skin is a complex, multistep process governed by physicochemical properties of the drug, formulation characteristics, and skin physiology.

3.1 Routes of Skin Permeation

Drug molecules can penetrate the skin via three main pathways:

1. Transcellular (Intracellular) Route

In this pathway, drug molecules pass directly through corneocytes. This route involves repeated partitioning between hydrophilic (protein-rich corneocytes) and lipophilic (intercellular lipids) domains, making it less favorable for most drugs [23].

2. Intercellular (Paracellular) Route

This is the most common pathway, where drug molecules diffuse through the lipid matrix between corneocytes. Lipophilic drugs preferentially utilize this route due to the continuous lipid domain [24].

3. Transappendageal (Shunt) Route

This pathway involves drug transport through hair follicles, sebaceous glands, and sweat ducts. Although it accounts for a small fraction of total skin surface area (<0.1%), it plays a significant role in the permeation of ions, large molecules, and nanoparticles [25].

3.2 Stepwise Mechanism of Drug Permeation

The permeation of drugs across the skin occurs through a series of sequential steps:

Step 1: Drug Release from Dosage Form

The drug is released from the transdermal patch and becomes available at the skin surface. This step depends on formulation factors such as polymer composition and drug solubility [26].

Step 2: Partitioning into Stratum Corneum

The drug partitions from the formulation into the stratum corneum. The partition coefficient (log P) plays a critical role in determining the extent of drug uptake into the skin [27].

Step 3: Diffusion through Stratum Corneum

Once inside the SC, the drug diffuses through the lipid matrix. This step is considered the rate-limiting step in transdermal drug delivery [28].

Step 4: Partitioning into Viable Epidermis

After crossing the SC, the drug partitions into the viable epidermis, which is more hydrophilic compared to the SC [29].

Step 5: Diffusion through Dermis

The drug diffuses through the dermis, where it encounters capillary networks. Due to the aqueous nature of this layer, hydrophilic drugs diffuse more readily [30].

Step 6: Systemic Absorption

Finally, the drug enters systemic circulation through dermal capillaries, achieving therapeutic plasma concentrations [31].

Figure 1: Mechanism of Skin Permeation

3.3 Mathematical Description of Skin Permeation

Drug permeation across the skin is commonly described by Fick’s First Law of Diffusion:

Where:

• J = Flux (amount of drug permeated per unit area per unit time)
• D = Diffusion coefficient
• K = Partition coefficient
• C = Drug concentration
• h = Thickness of the skin barrier

This equation highlights that permeation is directly proportional to the diffusion coefficient, partition coefficient, and drug concentration, and inversely proportional to the thickness of the skin barrier [31].

3.4 Factors Affecting Skin Permeation

1. Drug-Related Factors

• Molecular weight (<500 Da preferred)
• Lipophilicity (optimal log P: 1–3)
• Solubility
• Ionization (pKa)

2. Skin-Related Factors

• Thickness Of Stratum Corneum
• Hydration Level
• Age And Skin Condition
• Anatomical Site

3. Formulation Factors

• Type Of Polymer
• Use Of Permeation Enhancers
• Drug Concentration
• Vehicle System

4. Environmental Factors

• Temperature
• Humidity
• Occlusion

3.5 Strategies To Enhance Skin Permeation

To Overcome The Barrier Properties Of The Skin, Several Enhancement Techniques Are Employed:

• Chemical Enhancers (E.G., Alcohols, Terpenes)
• Vesicular Systems (Liposomes, Ethosomes)
• Physical Methods (Microneedles, Iontophoresis, Sonophoresis)
• Nanotechnology-Based Carriers

These Strategies Significantly Improve Drug Penetration And Are Widely Integrated Into Modern Transdermal Systems [12–14].

4. Quality By Design (Qbd) Approach In Herbal Transdermal Patch Development

Quality by Design (QbD) is a systematic, science- and risk-based approach to pharmaceutical development that emphasizes predefined objectives, process understanding, and control strategies to ensure consistent product quality. Regulatory authorities such as the International Council for Harmonisation strongly advocate QbD through guidelines like Q8 (R2), Q9, Q10, and Q14, which collectively promote lifecycle management and robust formulation development [11,12]. In the context of herbal transdermal patches, QbD plays a critical role in addressing variability in phytoconstituents, ensuring reproducibility, and optimizing formulation performance.

4.1 QbD Workflow for Herbal Transdermal Patches

The QbD framework involves a sequence of interrelated steps:

Step 1: Define Quality Target Product Profile (QTPP)

QTPP outlines the desired characteristics of the final product:

• Controlled drug release (24–72 h)
• Adequate adhesion properties
• Uniform drug content
• Optimal skin permeation
• Stability and safety

Step 2: Identify Critical Quality Attributes (CQAs)

CQAs are measurable properties that must be controlled to ensure product quality:

• Drug content uniformity
• Adhesive strength
• Tensile strength
• Moisture content
• In vitro drug release
• Skin permeation flux

Step 3: Determine Critical Material Attributes (CMAs)

• Polymer type (HPMC, PVA, Eudragit)
• Plasticizer concentration (PEG, glycerol)
• Herbal extract composition
• Permeation enhancers (terpenes, essential oils)

Step 4: Identify Critical Process Parameters (CPPs)

• Mixing time and speed
• Casting thickness
• Drying temperature
• Solvent evaporation rate

Step 5: Risk Assessment

Tools used:

• Ishikawa (Fishbone diagram)
• Failure Mode and Effects Analysis (FMEA)
• Risk Priority Number (RPN)

Step 6: Design of Experiments (DoE)

DoE is used to:

• Identify significant variables
• Optimize formulation
• Establish mathematical models

Step 7: Design Space

A multidimensional region where CQAs remain within acceptable limits.

Step 8: Control Strategy

• In-process controls
• Real-time monitoring (PAT tools)
• Batch consistency assurance

4.2 QbD WORKFLOW DIAGRAM

Table 1: DoE for Optimization of Herbal Transdermal Patch

4.4 TYPES OF Does USED IN TDDS

• Factorial Design (2?): Screening variables
• Box–Behnken Design: Optimization with fewer runs
• Central Composite Design (CCD): Response surface modeling
• D-optimal Design: Custom experimental conditions

4.5 ROLE OF QbD IN HERBAL TDDS

QbD provides:

• Improved product understanding
• Reduced batch failures
• Enhanced reproducibility
• Regulatory flexibility
• Cost-effective development

4.6 RECENT ADVANCES IN QbD APPLICATION

Recent studies (2021–2025) highlight:

• Integration with Artificial Intelligence (AI) for predictive modeling
• Use of Process Analytical Technology (PAT)
• Application in nanocarrier-based transdermal systems
• Real-time quality monitoring

5. FORMULATION OF HERBAL TRANSDERMAL PATCHES

The formulation of herbal transdermal patches involves the systematic selection and optimization of polymers, plasticizers, permeation enhancers, and herbal active constituents to achieve controlled drug release and effective skin permeation. Unlike synthetic drugs, herbal formulations present unique challenges due to their multicomponent nature, variability in phytoconstituents, and potential instability. Therefore, integrating formulation strategies with a Quality by Design (QbD) approach is essential for achieving reproducible and high-quality products [30,22].

5.1 Selection of Herbal Active Constituents

The choice of herbal drug is a critical step in formulation development. Suitable phytoconstituents should possess:

• Low molecular weight (<500 Da)
• Adequate lipophilicity (log P between 1–3)
• High potency (low dose requirement)
• Stability under formulation conditions
• Non-irritant and non-sensitizing properties

Examples of Herbal Drugs Used in TDDS